Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
AMBELVIST (GADOQUATRANE) | LOERadar
Viewing data from:
Latest
2026-10-01
2026-09-01
2026-08-03
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
AMBELVIST
NDA
Get alerts
GADOQUATRANE | N219627 | BAYER HEALTHCARE PHARMACEUTICALS INC
6 strengths
6 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
6 unique patents, 1 exclusivity by expiration date
All strengths
0.5158GM/2ML (257.9MG/ML)
1.93425GM/7.5ML (257.9MG/ML)
2.579GM/10ML (257.9MG/ML)
3.8685GM/15ML (257.9MG/ML)
7.737GM/30ML (257.9MG/ML)
16.7635GM/65ML (257.9MG/ML)
Active (6)
Today
Exclusivity
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
Today
10137209
May. 30, 2036
10722601
May. 30, 2036
11491245
May. 30, 2036
11944690
May. 19, 2040
12303573
Nov. 21, 2039
12478696
May. 30, 2036
NCE
Jun. 12, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (6)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 0.5158GM/2ML (257.9MG/ML)
RLD
6 patents
1 exclusivity
▴
SOLUTION;INTRAVENOUS | Approved: Jun 12, 2026
Patents (6)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
10137209
May 30, 2036
—
Yes
—
U-4424
METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM)
—
10722601
May 30, 2036
—
Yes
—
U-4424
METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM)
—
11491245
May 30, 2036
—
Yes
—
—
—
11944690
May 19, 2040
—
—
Yes
—
—
12303573
Nov 21, 2039
—
—
Yes
—
—
12478696
May 30, 2036
—
Yes
—
—
—
Exclusivities (1)
Code
Date
Status
NCE
Jun 12, 2031
Active
#002 — 1.93425GM/7.5ML (257.9MG/ML)
RLD
6 patents
1 exclusivity
▾
SOLUTION;INTRAVENOUS | Approved: Jun 12, 2026
#003 — 2.579GM/10ML (257.9MG/ML)
RLD
6 patents
1 exclusivity
▾
SOLUTION;INTRAVENOUS | Approved: Jun 12, 2026
#004 — 3.8685GM/15ML (257.9MG/ML)
RLD
6 patents
1 exclusivity
▾
SOLUTION;INTRAVENOUS | Approved: Jun 12, 2026
#005 — 7.737GM/30ML (257.9MG/ML)
RLD
6 patents
1 exclusivity
▾
SOLUTION;INTRAVENOUS | Approved: Jun 12, 2026
#006 — 16.7635GM/65ML (257.9MG/ML)
RLD
6 patents
1 exclusivity
▾
SOLUTION;INTRAVENOUS | Approved: Jun 12, 2026